Chromophobe Renal Cell Carcinoma

Symptoms, Doctors, Treatments, Advances & More

Dr. Michael A. Carducci is the AEGON Professor in Prostate Cancer Research at the Johns Hopkins University School of Medicine. He serves as the Vice Chair of Solid Tumor Oncology in the Department of Oncology. Dr. Carducci has an expertise in various types of cancer including prostate, kidney, and testicular. He also has an expertise in clinical trials, pain and palliative care for oncology, urological oncology, urology and medical oncology. A graduate of Georgetown University, Dr. Carducci received his medical degree with high distinction from Wayne State University School of Medicine. He completed an internal medicine internship, residency and chief residency at the University of Colorado Health Sciences Center. He went on to complete medical oncology and research fellowships at the Johns Hopkins Oncology Center at Johns Hopkins Hospital. He was promoted to Professor of Oncology and Urology in 2008 and installed into the inaugural AEGON Professorship in Prostate Cancer Research in 2009. He served as Co-Director of the GU Oncology program until 2013. In 2013, he assumed the leadership role of Associate Director for Clinical Research until being named Vice-Chair of Solid Tumor Oncology in 2024. A fellow of the American College of Physicians and a fellow of the American Society of Clinical Oncology, Dr. Carducci has received peer-reviewed funding for his clinical research from the National Cancer Institute, Department of Defense, and the Prostate Cancer Foundation. Mentorship of students, fellows, and junior faculty has been another focus of Dr. Carducci’s career in medicine, receiving numerous teaching awards. Dr. Carducci received the Michaele Christian Award and Lectureship for Oncology Drug Development at the National Cancer Institute in 2011. He chaired the Genitourinary Oncology Committee of ECOG-ACRIN from 2011-2024. In this role, he served on the GU Steering Committee for the NCI. Dr. Carducci is a member of the Investigational Drug Steering Committee for the NCI, and chaired that Committee for four years. He served as Associate Editor for GU Cancers for the Journal of Clinical Oncology from 2013-2024. Overall, his clinical research focus is on the development and evaluation of new therapies for urologic cancers. Incorporation of pharmacodynamics, novel biomarkers, and targeted imaging has been key elements of many of the trials led by Dr. Carducci. To complete these studies, Dr. Carducci facilitates and brings together a multidisciplinary team from urologists, radiation oncologists, pathologists, biostatisticians, and medical oncologists. Other areas of interest include palliative and end of life care, survivorship, and use of patient reported outcomes in clinical research and care. This provider is registered with the Florida Department of Health to perform telehealth services for patients in Florida. Dr. Carducci is rated as an Elite provider by MediFind in the treatment of Chromophobe Renal Cell Carcinoma. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Chromophobe Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Hormone Replacement Therapy (HRT), and Prostatectomy. Dr. Carducci is board certified in American Board Of Internal Medicine.

Richard Vanlangendonck, MD is a urologist at Intermountain Health’s Heber Valley Specialty Clinic in Hever City, Utah, and Jerry & Kathleen Grundhofer Clinic – Urology in Park City, Utah. He supports patients in Park City, Snyderville, Kamas, Francis, Woodland, Heber City, and surrounding communities, treating prostate cancer, kidney cancer, adrenal cancer, bladder cancer, and more. His clinical interests focus on robotic surgery for the treatment of prostate and kidney cancer. He is passionate about this technology's advanced capabilities, allowing for precise and minimally invasive procedures that significantly benefit his patients. Dr. Vanlangendonck is deeply committed to providing his patients with the highest standard of care. Guided by his philosophy of being the best doctor and person he can be, he treats each individual with compassion and respect. Committed to excellence, the Louisiana native continually strives to perfect his craft. He takes great pride in delivering outstanding patient care and ensuring that each patient is satisfied.Potential patients should know that Dr. Vanlangendonck excels in his field and is passionate about his expertise. He brings this expertise to his practice every day, providing his patients with the highest level of care and support throughout their wellness journey.Conditions Treated: Prostate CancerKidney CancerAdrenal CancerBladder CancerKidney and Ureteral StonesBenign Prostatic Hyperplasia Elevated PSAVoiding Dysfunction Erectile DysfunctionProcedures Performed: Robotic Urologic Surgery for Urologic Cancers Robotic Urologic Surgery for Urinary Obstruction Ureteroscopy Transurethral Surgery for Bening and Malignant DiseaseCystoscopyTransrectal and Transperineal Ultrasound with Prostate BiopsyVasectomy. Dr. Vanlangendonck is rated as a Distinguished provider by MediFind in the treatment of Chromophobe Renal Cell Carcinoma. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), WT1-Related Wilms Tumor Syndromes, Chromophobe Renal Cell Carcinoma, Reconstructive Urology Surgery, and Nephrectomy. Dr. Vanlangendonck is board certified in American Board Of Urology. Dr. Vanlangendonck is currently accepting new patients.

Timothy Lestingi is a Hematologist and an Oncologist practicing medicine in Park Ridge, Illinois. Dr. Lestingi is rated as a Distinguished provider by MediFind in the treatment of Chromophobe Renal Cell Carcinoma. He is also highly rated in 28 other conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, Ureteroscopy, and Gastrostomy. Dr. Lestingi is board certified in American Board Of Internal Medicine, Medical Oncology.